Abstract
The endogenous cannabinoid system is an ubiquitous lipid signalling system that appeared early in evolution and which has important regulatory functions throughout the body in all vertebrates. The main endocannabinoids (endogenous cannabis-like substances) are small molecules derived from arachidonic acid, anandamide (arachidonoylethanolamide) and 2-arachidonoylglycerol. They bind to a family of G-protein-coupled receptors, of which the cannabinoid CB1 receptor is densely distributed in areas of the brain related to motor control, cognition, emotional responses, motivated behaviour and homeostasis. Outside the brain, the endocannabinoid system is one of the crucial modulators of the autonomic nervous system, the immune system and microcirculation. Endocannabinoids are released upon demand from lipid precursors in a receptor-dependent manner and serve as retrograde signalling messengers in GABAergic and glutamatergic synapses, as well as modulators of postsynaptic transmission, interacting with other neurotransmitters, including dopamine. Endocannabinoids are transported into cells by a specific uptake system and degraded by two well-characterized enzymes, the fatty acid amide hydrolase and the monoacylglycerol lipase. Recent pharmacological advances have led to the synthesis of cannabinoid receptor agonists and antagonists, anandamide uptake blockers and potent, selective inhibitors of endocannabinoid degradation. These new tools have enabled the study of the physiological roles played by the endocannabinoids and have opened up new strategies in the treatment of pain, obesity, neurological diseases including multiple sclerosis, emotional disturbances such as anxiety and other psychiatric disorders including drug addiction. Recent advances have specifically linked the endogenous cannabinoid system to alcoholism, and cannabinoid receptor antagonism now emerges as a promising therapeutic alternative for alcohol dependence and relapse. Medical Council on Alcohol 2005; all rights reserved.
Author supplied keywords
- *endocannabinoid/ec [Endogenous Compound]
- 1 (2,4 dichlorophenyl) 5 (4 iodophenyl) 4 methyl n
- 2 arachidonoylglycerol/ec [Endogenous Compound]
- 2,3 dihydro 5 methyl 3 (morpholinomethyl) 6 (1 nap
- 4 (1,1 dimethylheptyl) 1',2',3',4',5',6' hexahydro
- 4 [6 methoxy 2 (4 methoxyphenyl) 3 benzofuranylcar
- 5 (4 bromophenyl) 1 (2,4 dichlorophenyl) 4 ethyl n
- 5 (4 chloro 3 methylphenyl) 1 (4 methylbenzyl) n (
- 6 iodo 3 (4 methoxybenzoyl) 2 methyl 1 (2 morpholi
- G protein coupled receptor/ec [Endogenous Compound
- GABAergic transmission
- acylglycerol lipase/ec [Endogenous Compound]
- alcoholism
- anandamide/ec [Endogenous Compound]
- anxiety disorder/dt [Drug Therapy]
- arachidonic acid derivative/ec [Endogenous Compoun
- arachidonic acid/ec [Endogenous Compound]
- article
- autonomic nervous system
- brain function
- cannabinoid 1 receptor/ec [Endogenous Compound]
- cannabinoid receptor agonist/an [Drug Analysis]
- cannabinoid receptor agonist/dv [Drug Development]
- cannabinoid receptor agonist/pd [Pharmacology]
- cannabinoid receptor antagonist/an [Drug Analysis]
- cannabinoid receptor antagonist/ct [Clinical Trial
- cannabinoid receptor antagonist/dt [Drug Therapy]
- cannabinoid receptor antagonist/dv [Drug Developme
- cannabinoid receptor antagonist/po [Oral Drug Admi
- cell function
- clinical trial
- dexanabinol/pd [Pharmacology]
- disease association
- dopamine/ec [Endogenous Compound]
- drug antagonism
- drug dependence/dt [Drug Therapy]
- drug receptor binding
- drug targeting
- emotional disorder/dt [Drug Therapy]
- fatty acid amidase/ec [Endogenous Compound]
- human
- icosanoid metabolism
- icosanoid/an [Drug Analysis]
- icosanoid/dv [Drug Development]
- immune system
- immunomodulation
- lh 21/an [Drug Analysis]
- lh 21/dv [Drug Development]
- lh 21/pd [Pharmacology]
- lipid analysis
- lipid degradation
- lipid transport
- lipogenesis
- mental disease/dt [Drug Therapy]
- methanandamide/an [Drug Analysis]
- methanandamide/dv [Drug Development]
- methanandamide/pd [Pharmacology]
- microcirculation
- multiple sclerosis/dt [Drug Therapy]
- n (3 furylmethyl)arachidonamide/an [Drug Analysis]
- n (3 furylmethyl)arachidonamide/dv [Drug Developme
- n (3 furylmethyl)arachidonamide/pd [Pharmacology]
- n (4 hydroxyphenyl)arachidonamide/an [Drug Analysi
- n (4 hydroxyphenyl)arachidonamide/dv [Drug Develop
- n (4 hydroxyphenyl)arachidonamide/pd [Pharmacology
- neuroanatomy
- neurologic disease/dt [Drug Therapy]
- neuromodulation
- nonhuman
- obesity/dt [Drug Therapy]
- pain/dt [Drug Therapy]
- pathophysiology
- postsynaptic potential
- priority journal
- protein synthesis
- pyrazole derivative/an [Drug Analysis]
- pyrazole derivative/ct [Clinical Trial]
- pyrazole derivative/dt [Drug Therapy]
- pyrazole derivative/dv [Drug Development]
- pyrazole derivative/po [Oral Drug Administration]
- regulatory mechanism
- rimonabant/an [Drug Analysis]
- rimonabant/ct [Clinical Trial]
- rimonabant/dt [Drug Therapy]
- rimonabant/dv [Drug Development]
- rimonabant/po [Oral Drug Administration]
- signal transduction
- structure activity relation
- systematic review
- triazole derivative/an [Drug Analysis]
- triazole derivative/dv [Drug Development]
- triazole derivative/pd [Pharmacology]
- unclassified drug
- unindexed drug
- vertebrate
- virodhamine/ec [Endogenous Compound]
Cite
CITATION STYLE
F.R., de F., I., del A., F.J., B.-S., A., B., A., C., & M., N. (2005). The endocannabinoid system: Physiology and pharmacology. Alcohol and Alcoholism. F.R. de Fonseca, Fundacion IMABIS, Hospital Carlos Haya de Malaga, Avenida Carlos Haya 82, 29010 Malaga, Spain. E-mail: fernando.rodriguez.exts@juntadeandalucia.es: Oxford University Press. Retrieved from http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed7&NEWS=N&AN=2005048821
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.